Journal article icon

Journal article

Sequelae and survivorship in patients treated with 131 I-MIBG therapy

Abstract:

Background: 131 I-meta-iodobenzylguanidine (131 I-MIBG) has been in therapeutic use since 1980s. Newer treatment modalities are emerging for neuroendocrine tumours (NETs) and chromaffin cell tumours (CCTs), but many of these do not yet have adequate long-term follow-up to determine their longer term efficacy and sequelae. Methods: Fifty-eight patients with metastatic NETs and CCTs who had received 131 I-MIBG therapy between 2000 and 2011 were analysed. Survival and any long-term haematologica...

Expand abstract

Actions


Access Document


Publisher copy:
10.1038/bjc.2013.365

Authors


Grossman, AB More by this author
Goddard, I More by this author
Amendra, D More by this author
Shieh, SCC More by this author
Expand authors...
Journal:
British Journal of Cancer
Volume:
109
Issue:
3
Pages:
565-572
Publication date:
2013-08-06
DOI:
EISSN:
1532-1827
ISSN:
0007-0920
URN:
uuid:9fc96bdc-9b73-4e80-9a46-575927da435e
Source identifiers:
426360
Local pid:
pubs:426360
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP